Skip to Content
U.S. National Institutes of Health
Cancer Diagnosis Program Cancer Imaging Program Cancer Therapy Evaluation Program Developmental Therapeutics Program Radiation Research Program Translational Research Program Biometric Research Branch Office of Cancer Complementary and Alternative Medicine
Last Updated: 04/25/2012


Prioritizing Targeted Agents for Pediatric Clinical Evaluation

Testing whether new targeted agents are effective in pediatrics has become critical for CTEP. Substantial efforts have been devoted to finding an effective mechanism for such testing.

The Pediatric Preclinical Testing Program (PPTP) presented testing results for seven molecularly targeted agents at national meetings in 2007, including results for the following:

Particularly promising results were observed for ABT-263 against the PPTP’s acute lymphoblastic leukemia (ALL) panel. Three of six ALL xenografts achieved complete remissions to ABT-263, with two of these remissions being maintained for 3 weeks following treatment cessation. In contrast to the high activity for ABT-263 in the ALL panel, little activity was observed for ABT-263 as a single agent against the PPTP’s solid tumor xenografts. The xenografts of the ALL panel had higher levels of Bcl-2 expression than the solid tumor xenografts.

Promising results were also noted for the anti-IGF-1 receptor monoclonal antibody 19D12 against the PPTP’s osteosarcoma and Ewing sarcoma panels. Complete remissions were observed for one of five Ewing sarcoma xenografts and for two of six osteosarcoma xenografts.